Online inquiry

IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4088MR)

This product GTTS-WQ4088MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4088MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1764MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ12242MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ13177MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ8386MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3839MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ1480MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ9306MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW